HBx dysregulation of miR-155 can occur due to histone modifications like histone deacetylase inhibitors (HDAC-I) or the repression of polycomb proteins (EZH2) can contribute to upregulated miR-155 expression in HBV-HCC pathways (43, 66, 67). Here, EZH2 is linked to hepatocellular carcinoma.